Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Deeks SG.

J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33. Review.

PMID:
11264999
2.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

3.
4.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
5.

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM.

Virology. 2001 Jul 5;285(2):193-203.

6.

NNRTIs: a neglected class.

Cadman J.

GMHC Treat Issues. 1998 Sep;12(9):6-10.

PMID:
11365807
7.

In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.

Gianotti N, Boeri E, Maillard M, Serra G, Ratti D, Gallotta G, Vacchini D, Tremolada Y, Castagna A.

New Microbiol. 2004 Apr;27(2 Suppl 1):111-7.

PMID:
15646073
8.
9.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
10.

[Non-nucleoside reverse transcriptase inhibitors].

Joly V, Yeni P.

Ann Med Interne (Paris). 2000 Jun;151(4):260-7. Review. French.

PMID:
10922953
11.

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arnó A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B, Larder B.

AIDS. 2000 Jan 28;14(2):F1-7.

PMID:
10708276
12.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC.

Antimicrob Agents Chemother. 2000 Mar;44(3):794-7.

13.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95. Epub 2004 Apr 13.

PMID:
15116307
14.

Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.

Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, Staszewski S.

Antimicrob Agents Chemother. 1998 Dec;42(12):3123-9.

15.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
16.

Efavirenz: resistance and cross-resistance.

Clotet B.

Int J Clin Pract Suppl. 1999 Jun;103:21-5. Review.

PMID:
10622039
17.

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

18.

In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.

Kollmann C, Tremblay C, Giguel F, Chou TC, Hirsch MS.

Antivir Ther. 2001 Jun;6(2):143-4. No abstract available.

PMID:
11491419
19.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.

Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P.

HIV Clin Trials. 2002 Jan-Feb;3(1):36-44.

PMID:
11819184
20.

Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.

Quiros-Roldan E, Airoldi M, Moretti F, Fausti C, Pan A, Casari S, Torti C, Castelli F, Carosi G.

J Clin Lab Anal. 2002;16(2):76-8.

PMID:
11948795

Supplemental Content

Support Center